298 related articles for article (PubMed ID: 28512255)
1. Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growth.
Ranjan A; Wright S; Srivastava SK
Oncotarget; 2017 Jul; 8(29):47632-47641. PubMed ID: 28512255
[TBL] [Abstract][Full Text] [Related]
2. Penfluridol suppresses glioblastoma tumor growth by Akt-mediated inhibition of GLI1.
Ranjan A; Srivastava SK
Oncotarget; 2017 May; 8(20):32960-32976. PubMed ID: 28380428
[TBL] [Abstract][Full Text] [Related]
3. Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion.
Otvos B; Silver DJ; Mulkearns-Hubert EE; Alvarado AG; Turaga SM; Sorensen MD; Rayman P; Flavahan WA; Hale JS; Stoltz K; Sinyuk M; Wu Q; Jarrar A; Kim SH; Fox PL; Nakano I; Rich JN; Ransohoff RM; Finke J; Kristensen BW; Vogelbaum MA; Lathia JD
Stem Cells; 2016 Aug; 34(8):2026-39. PubMed ID: 27145382
[TBL] [Abstract][Full Text] [Related]
4. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ
Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175
[TBL] [Abstract][Full Text] [Related]
5. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
6. Metformin Prevents Peritoneal Dissemination
Hirayama T; Nagata Y; Nishida M; Matsuo M; Kobayashi S; Yoneda A; Kanetaka K; Udono H; Eguchi S
Anticancer Res; 2019 Sep; 39(9):4699-4709. PubMed ID: 31519569
[TBL] [Abstract][Full Text] [Related]
7. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis.
Alban TJ; Alvarado AG; Sorensen MD; Bayik D; Volovetz J; Serbinowski E; Mulkearns-Hubert EE; Sinyuk M; Hale JS; Onzi GR; McGraw M; Huang P; Grabowski MM; Wathen CA; Ahluwalia MS; Radivoyevitch T; Kornblum HI; Kristensen BW; Vogelbaum MA; Lathia JD
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385717
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma.
Siret C; Collignon A; Silvy F; Robert S; Cheyrol T; André P; Rigot V; Iovanna J; van de Pavert S; Lombardo D; Mas E; Martirosyan A
Front Immunol; 2019; 10():3070. PubMed ID: 32038621
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
Vo MC; Yang S; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Lee JJ
Front Immunol; 2018; 9():1798. PubMed ID: 30123221
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
[TBL] [Abstract][Full Text] [Related]
11. Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.
Cresswell GM; Wang B; Kischuk EM; Broman MM; Alfar RA; Vickman RE; Dimitrov DS; Kularatne SA; Sundaram CP; Singhal S; Eruslanov EB; Crist SA; Elzey BD; Ratliff TL; Low PS
Cancer Res; 2021 Feb; 81(3):671-684. PubMed ID: 33203700
[TBL] [Abstract][Full Text] [Related]
12. Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma.
Richard SA
Dis Markers; 2020; 2020():8844313. PubMed ID: 33204365
[TBL] [Abstract][Full Text] [Related]
13. Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression.
Alban TJ; Bayik D; Otvos B; Rabljenovic A; Leng L; Jia-Shiun L; Roversi G; Lauko A; Momin AA; Mohammadi AM; Peereboom DM; Ahluwalia MS; Matsuda K; Yun K; Bucala R; Vogelbaum MA; Lathia JD
Front Immunol; 2020; 11():1191. PubMed ID: 32625208
[TBL] [Abstract][Full Text] [Related]
14. Altered Metabolism in Glioblastoma: Myeloid-Derived Suppressor Cell (MDSC) Fitness and Tumor-Infiltrating Lymphocyte (TIL) Dysfunction.
Di Ianni N; Musio S; Pellegatta S
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923299
[TBL] [Abstract][Full Text] [Related]
15. Canonical NFκB signaling in myeloid cells is required for the glioblastoma growth.
Achyut BR; Angara K; Jain M; Borin TF; Rashid MH; Iskander ASM; Ara R; Kolhe R; Howard S; Venugopal N; Rodriguez PC; Bradford JW; Arbab AS
Sci Rep; 2017 Oct; 7(1):13754. PubMed ID: 29062041
[TBL] [Abstract][Full Text] [Related]
16. Atovaquone Suppresses Triple-Negative Breast Tumor Growth by Reducing Immune-Suppressive Cells.
Gupta N; Gaikwad S; Kaushik I; Wright SE; Markiewski MM; Srivastava SK
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068008
[TBL] [Abstract][Full Text] [Related]
17. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
Front Immunol; 2019; 10():1273. PubMed ID: 31214202
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.
Lee-Chang C; Rashidi A; Miska J; Zhang P; Pituch KC; Hou D; Xiao T; Fischietti M; Kang SJ; Appin CL; Horbinski C; Platanias LC; Lopez-Rosas A; Han Y; Balyasnikova IV; Lesniak MS
Cancer Immunol Res; 2019 Dec; 7(12):1928-1943. PubMed ID: 31530559
[TBL] [Abstract][Full Text] [Related]
19. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
[TBL] [Abstract][Full Text] [Related]
20. Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome.
González-Tablas Pimenta M; Otero Á; Arandia Guzman DA; Pascual-Argente D; Ruíz Martín L; Sousa-Casasnovas P; García-Martin A; Roa Montes de Oca JC; Villaseñor-Ledezma J; Torres Carretero L; Almeida M; Ortiz J; Nieto A; Orfao A; Tabernero MD
Brain Pathol; 2021 Mar; 31(2):365-380. PubMed ID: 33314398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
